Unless and Until they get rid of half the BOD and half the upper management Longs are doomed.
Lots of pleasure is found in watching the longs on this board make complete jerks of themselves. Even with 5 Underwriting Investment banks intervening with pps using fake price targets, share games, fake loss projections the pps is up 90 cents ( taken into account the 1:10 reverse split) since the reverse split. Longs are underwater still. So even with all the help of 5 banksters fighting hard the market knows this is junk and is standing strong in the face of blatant manipulation. When the banksters contracts expire pps will tank to where it rightfully belongs.
Longs like to pepper this board with crazy delusions and lies. They look at 1 month after the RS as a reason to be joyful and pretend pps hasn't gone down due to factors of this 20 year old company with only a poor selling diet pill. They ignore fact of 5 Investment bank agents supporting pps. They are keeping pps artificially high to dump their discounted Underwritten and greenshoe shares. These Underwriters are even now saying losses will be less. Again they have shares to dump. PPS will go lower as the investment banks leave .PUMPERS HAVE BEEN EXPOSED and EXUBERANCE OF LONGS BUILT ON NOTHING BUT INVESTMENT BANK GAMES WILL LEAD TO MOANING.
THEY ARE DESPERATELY TRYING TO KEEP THE PRICE CLOSE TO THE OFFERING BUT THEY WILL FAIL...HISTORY TELLS US THIS SCAM COMPANY HAS SCAMMED THEIR INVESTORS ONCE MORE FOR THE UMTEENTH TIME...AS USUAL MANAGEMENT GOT THE MONEY AND SHAREHOLDERS GOT SCREWED...dyodd
Axon pps down since presented Nelotanserin Data at Alzheimer's Association International Conference. That's bad for Arna.
Belviq- as of 2017the poorest seller and least wanted of oral anti-obesity medications. Injection Saxenda is even crushing it on revenues Pumpers and desperate underwaters re-hash 3 year articles from hong kong..LOL 13 yr old Etrasimod was bypassed by Celg and other big pharmas and hasn't completed P2 studies yet. Have now reduced enrollment to less than 1/2 Ozanimod UC phase 2 trials. Arna can't compete in drug spaces, but does compete very well in # of BOD members
PAH phase 2 data from old apd 811 musta really stunk. PPS has to rise 76% to get to pps on the day orphan status was announced in 2014 4 years after phase 1 data was given. And that was in the hayday of Bel with it's huge sales force, tv advertising, no contrave, etc. Wow ! What a POS stock.
Friends, our company has at least 50% more BOD and highly paid leaders than it needs. Too many employees to if you ask me. We only have 1 drug on the market. Etrasimod is going nowhere fast and won't save the company. Neither will Ralinepag or apd371. One of those programs need to be stopped to save money. The San Diego HQ is too large and expensive for our needs and the Swiss plant needs to go. Here's the short story for Weds. July 19 2017. 61.6% of trades shorted. Remember, Don't trust pumpers. If you go out of doors check for ticks. Stay tuned. Cheers !
Etrasimod is heading to disaster. Arna cut it's enrollment and has said other S1P1 patents will harm its potential commercialization. It has no chance against Celg's S1P1. Completion of mandated CVOT safety trials for Belflop is a red herring and will mean nothing for sales, doesn't change the drug's marginality.. CVOT may already be showing side effects FDA is concerned about according to recent article in SA.
Friends, saw something that makes one sick. Arna has a BOD and leadership team that equals the powerhouse JNJ and it's packed with MORE BOD and LEADERS than Celg and AbbVIE. Disgusting!!! BP won't touch this co.with so many pigs at the trough let alone with the weak pipe and dud Belviq. Monday July 17 saw 56% of trades went short and Tues July 18,2017 had 50% going short. Don't trust pumpers -example of pumper lie is how pps was going to $40, $70,$100 immediately upon P2data from old pah drug. OOPS, got diluted again instead !! If out of doors check for ticks. Stay tuned. Cheers.
ARNA has 1 drug. It's a flop diet pill. Arna had 92% revenue drop 1Q17. ARNA does another dilution in 2017 after a RS. last week it was announced Cantor Fitzgerald is a joint Underwriter with shares to dump. To help dump their shares cantor reaffirms buy rating. To note Cantor and the other Underwriters can short arna
Looks like low volume pps manipulation to trick you to buy. 5 Underwriters playing share ping pong to jack the pps as they unload their discounted shares and prepare to short. Or are they shorting now? No reason to buy. Anything you buy can and will be used against you. 3 dilutions and RS in seven months. Don't fall for underwriter tricks. Dyodd
Me thinks the 5 bookers are fighting hard to prop pps to have a better short position.
Shares available to short. Last updated: Thu, 20.Jul.17 15:17EDT Symbol: ARNA Availability: 2'100'000 Exchanges: NASDAQ
This pump and dump scam never ends.
Lack of Fiduciary Duty. Amit secures his job on backs of shareholders and by bloating BOD and Insiders rewarding them with big pay and free shares from shareholder money. No reason for RS. He needs to explain why they reduced shares then added shares. Arna won't prosper Until amit is fired!
Don't be foolish and go long in this garbage. Only quick active day traders and shorts reap with this junk. Longs get burned. Day traders and Shorts always win with this POS.
AXON got world wide rights to Nelotanserin for $4m Five years after it failed a massive 900 P2 ARNA trial. Now AXON doing a study : Estimated Enrollment: 20 Study Start Date:December 2015 that arna pump squad exploits. No significance to ARNA
Careful. Looks like low volume pps manipulation by all the Underwriter agents. No reason to buy. Pah data likely false positive. Revenues expected to be lower 2Q. Don't fall for underwriter tricks. Anything you buy can and will be used against you. Diluted trapped longs can't recoup losses. DYODD
just pump and dump as usual. I don't care I sold before split took effect. All the pump, and now the Dump. Selling more shares to stay alive. What is there that any fool cant see.